Literature DB >> 18247111

What are the biochemical mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice?

Andrew N Carley1, David L Severson.   

Abstract

INTRODUCTION: It is generally accepted that diabetic hearts have an altered metabolic phenotype, with enhanced fatty acid (FA) utilization. The over-utilization of FA by diabetic hearts can have deleterious functional consequences, contributing to a distinct diabetic cardiomyopathy. The objective of this review will be to examine which biochemical mechanisms are responsible for enhanced FA utilization by diabetic hearts. METHODOLOGY AND
RESULTS: Studies were performed with db/db mice, a monogenic model of type 2 diabetes with extreme obesity and hyperglycemia. Perfused db/db hearts exhibit enhanced FA oxidation and esterification. Hypothesis 1: Cardiac FA uptake is enhanced in db/db hearts. The plasma membrane content of two FA transporters, fatty acid translocase/CD36 (FAT/CD36) and plasma membrane fatty acid binding protein (FABPpm), was increased in db/db hearts, consistent with hypothesis 1. Hypothesis 2: Cardiac FA oxidation is enhanced in db/db hearts due to mitochondrial alterations. However, the activity of carnitine palmitoyl transferase-1 (CPT-1) and sensitivity to inhibition by malonyl CoA was unchanged in mitochondria from db/db hearts. Furthermore, total malonyl CoA content was increased, not decreased as predicted for elevated FA oxidation. Finally, the content of uncoupling protein-3 was unchanged in db/db heart mitochondria.
CONCLUSION: Increased plasma membrane content of FA transporters (FAT/CD36 and FABPpm) will increase FA uptake into db/db cardiomyocytes and thus increase FA utilization. On the other hand, mitochondrial mechanisms do not contribute to elevated rates of FA oxidation in db/db hearts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18247111     DOI: 10.1007/s10557-008-6088-9

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  7 in total

1.  Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes.

Authors:  Karin Przyklenk; Michelle Maynard; Dale L Greiner; Peter Whittaker
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

2.  Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice.

Authors:  C Vecoli; J Cao; D Neglia; K Inoue; K Sodhi; L Vanella; K K Gabrielson; D Bedja; N Paolocci; A L'abbate; N G Abraham
Journal:  J Cell Biochem       Date:  2011-09       Impact factor: 4.429

Review 3.  Metabolic syndrome: from epidemiology to systems biology.

Authors:  Aldons J Lusis; Alan D Attie; Karen Reue
Journal:  Nat Rev Genet       Date:  2008-11       Impact factor: 53.242

4.  Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer.

Authors:  K J Mather; G D Hutchins; K Perry; W Territo; R Chisholm; A Acton; B Glick-Wilson; R V Considine; S Moberly; T R DeGrado
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-05       Impact factor: 4.310

5.  Mitochondria-targeted dodecyltriphenylphosphonium (C12TPP) combats high-fat-diet-induced obesity in mice.

Authors:  A V Kalinovich; C L Mattsson; M R Youssef; N Petrovic; M Ost; V P Skulachev; I G Shabalina
Journal:  Int J Obes (Lond)       Date:  2016-08-18       Impact factor: 5.095

Review 6.  The role of CD36 in cardiovascular disease.

Authors:  Hongyang Shu; Yizhong Peng; Weijian Hang; Jiali Nie; Ning Zhou; Dao Wen Wang
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

Review 7.  Diabetic cardiomyopathy.

Authors:  Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.